Sputnik V India manufacturing update: Panacea Biotec gets DCGI nod to produce Russia's COVID-19 vaccine- check ADVANTAGES of the vaccine here

Panacea Biotec Latest News: The Drug Controller General of India (DCGI) has approved biotechnology company Panacea Biotech to manufacture Russia's COVID-19 vaccine Sputnik V in India.

Panacea Biotec has also issued a press release in this regard. The biotechnology company has received the license to produce Sputnik V at Baddi, Himachal Pradesh.

See Zee Business Live TV Streaming Below:

It must be noted that Sputnik V was registered in India under the emergency use authorisation procedure in April 12, 2021 and vaccination against COVID-19 with Sputnik V started on May 14, 2021. The Russian Sputnik V COVID-19 vaccine has been registered in 67 countries with total population of over 3.5 billion.

As per the press release issued by Panacea Biotech, "The batches produced at Panacea Biotec’s facilities at Baddi, Himachal Pradesh were earlier shipped to the Gamaleya Center in Russia for quality control. The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli, Himachal Pradesh in India."

The release from the biotechnology company further stated that the vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots. The Sputnik V COVID-19 vaccine also have a number of other key advantages as per Panacea Biotec. They are as follows:

1) There are no strong allergies caused by Sputnik V vaccine

2) The storage temperature of Sputnik V at +2+8 C means that it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.

Regarding the manufacturing license for Sputnik V COVID-19 vaccine, Dr. Rajesh Jain, Managing Director, Panacea Biotech said, "“Panacea Biotec is delighted to announce the obtaining of the manufacturing license to produce Sputnik V vaccine in India. At this occasion, we thank the leadership of our Hon’ble Prime Minister in India’ vaccines.”